Skip to main content

Myeloproliferative and Myelodysplastic Neoplasms: The Past, Present, and Future

Original release date:
June 11, 2024
Access to this course expires on:  May 6, 2027 at 11:59 PM Pacific Time
CME 12

Course Description
In the era of the rapid development of new diagnostic modalities and novel targeted treatment options, a comprehensive diagnostic approach to myelodysplastic and myeloproliferative neoplasms becomes ever more critical. However, the rapidly evolving scientific and technological discoveries that have been continuously incorporated into the classification of myelodysplastic and/or myeloproliferative neoplasms significantly increase already complex hematopathology practice. (Hemato)pathologists are currently facing the following challenges:

  • How to stay abreast of this avalanche of data?
  • How to incorporate the data into my day-to-day practice?
  • What testing should I order to correctly classify myelodysplastic and myeloproliferative neoplasms?
  • How should my diagnosis be worded in the face of two new classifications of hematologic neoplasms (5th edition WHO and 2022 International Consensus Classifications).
This course, led by four experienced academic hematopathologists practicing at four large cancer centers, will answer all of these questions (and more) by reviewing cases of myeloid neoplasms with myelodysplastic and myeloproliferative features. Join us on the exciting journey from the past to the present and into the future!

Target Audience
Practicing academic and community pathologists, and pathologists-in-training

Learning Objectives
Upon completion of this educational activity, learners will be able to:
  • Become familiar with the changes to classification of myelodysplastic and myeloproliferative neoplasms and overlap myelodysplastic/myeloproliferative neoplasms.
  • Identify critical ancillary testing needed for accurate classification, as informed by the clinical scenario or morphologic findings.
  • Recognize morphologic and immunophenotypic correlates of underlying genetic lesions in MDS/MPN and related neoplasms.
  • Generate a comprehensive (and comprehensible), clinically relevant, integrated pathology report that includes the most updated classification systems.

Continuing Medical Education
The United States and Canadian Academy of Pathology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The United States and Canadian Academy of Pathology designates this enduring material for a maximum of 12 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to USCAP and to learners any financial relationship(s) that have occurred within the last 24 months with any commercial interest(s) whose products or services are related to the CME content. USCAP has reviewed all disclosures and mitigated all identified conflicts of interest, as applicable.

The following faculty reported no relevant financial relationships: Olga Pozdnyakova, MD, PhD, Robert P. Hasserjian, MD, Sanam Loghavi, MD, Emily F. Mason, MD, PhD
The following IM coordinator reported no relevant financial relationships: Daniel A. Arber, MD

USCAP staff associated with the development of content for this activity reported no relevant financial relationships.

To earn CME credit, all learners must complete the evaluation. Learners can now self-submit CME on all earned certificates. View and print your certificates by clicking here.

USCAP members receive a discount on all e-Learning courses. Not A Member? Click Here to sign up today.